Deep Eutectic Solvents for Subcutaneous Delivery of Protein Therapeutics

Alexander M. Curreri,Jayoung Kim,Michael Dunne,Pavimol Angsantikul,Morgan Goetz,Yongsheng Gao,Samir Mitragotri

DOI: https://doi.org/10.1002/advs.202205389

IF: 15.1

2023-01-17

Advanced Science

Abstract:Here the use of deep eutectic solvents in biologic formulations is reported to improve the pharmacokinetic properties of insulin and monoclonal antibodies. The underlying mechanisms are reported and the safety of deep eutectic biologics formulations in a rodent model is evaluated. Proteins are among the most common therapeutics for the treatment of diabetes, autoimmune diseases, cancer, and metabolic diseases, among others. Despite their common use, current protein therapies, most of which are injectables, have several limitations. Large proteins such as monoclonal antibodies (mAbs) suffer from poor absorption after subcutaneous injections, thus forcing their administration by intravenous injections. Even small proteins such as insulin suffer from slow pharmacokinetics which poses limitations in effective management of diabetes. Here, a deep eutectic‐based delivery strategy is used to offer a generalized approach for improving protein absorption after subcutaneous injections. The lead formulation enhances absorption of mAbs after subcutaneous injections by ≈200%. The same composition also improves systemic absorption of subcutaneously injected insulin faster than Humalog, the current gold‐standard of rapid acting insulin. Mechanistic studies reveal that the beneficial effect of deep eutectics on subcutaneous absorption is mediated by their ability to reduce the interactions of proteins with the subcutaneous matrix, especially collagen. Studies also confirm that these deep eutectics are safe for subcutaneous injections. Deep eutectic‐based formulations described here open new possibilities for subcutaneous injections of therapeutic proteins.

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry